Literature DB >> 26372038

Immunotherapies for bladder cancer: a new hope.

Farhad Fakhrejahani1, Yusuke Tomita, Agnes Maj-Hes, Jane B Trepel, Maria De Santis, Andrea B Apolo.   

Abstract

PURPOSE OF REVIEW: We review recent data on immunotherapies for bladder cancer and discuss strategies to maximize the antitumor effect of immunotherapy in solid tumors. RECENT
FINDINGS: Anti-programmed death ligand 1 has shown promise in advanced bladder cancer. Clinical trials of immune checkpoint inhibitors as monotherapy or in combination are underway. Here we review strategies for enhancing antitumor immunity using immunomodulating agents or combination treatments that may increase tumor response.
SUMMARY: Combining immune checkpoint inhibitors with other treatment modalities may lead to the development of new treatment strategies in advanced bladder cancer; however, identifying predictive biomarkers is essential for appropriate patient selection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26372038      PMCID: PMC6777558          DOI: 10.1097/MOU.0000000000000213

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  123 in total

1.  CTLA-4: not all costimulation is stimulatory.

Authors:  Hugh Auchincloss; Laurence A Turka
Journal:  J Immunol       Date:  2011-10-01       Impact factor: 5.422

Review 2.  Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

Authors:  Kazuo Sugamura; Naoto Ishii; Andrew D Weinberg
Journal:  Nat Rev Immunol       Date:  2004-06       Impact factor: 53.106

3.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

4.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

5.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

6.  Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.

Authors:  E Xylinas; B D Robinson; L A Kluth; B G Volkmer; R Hautmann; R Küfer; M Zerbib; E Kwon; R H Thompson; S A Boorjian; S F Shariat
Journal:  Eur J Surg Oncol       Date:  2013-09-18       Impact factor: 4.424

7.  Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss.

Authors:  Vincent Ling; Paul W Wu; Vikki Spaulding; Jan Kieleczawa; Deborah Luxenberg; Beatriz M Carreno; Mary Collins
Journal:  Genomics       Date:  2003-09       Impact factor: 5.736

Review 8.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 9.  Programmed death ligand 2 in cancer-induced immune suppression.

Authors:  Esdy N Rozali; Stanleyson V Hato; Bruce W Robinson; Richard A Lake; W Joost Lesterhuis
Journal:  Clin Dev Immunol       Date:  2012-04-29

10.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

View more
  8 in total

Review 1.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

Review 2.  Immunotherapy in genitourinary malignancies.

Authors:  Max M Wattenberg; Lawrence Fong; Ravi A Madan; James L Gulley
Journal:  Curr Opin Urol       Date:  2016-11       Impact factor: 2.309

3.  MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.

Authors:  Lin Zhu; Xianhui Liu; Weiyu Zhang; Hao Hu; Qi Wang; Kexin Xu
Journal:  BMC Cancer       Date:  2022-05-17       Impact factor: 4.638

Review 4.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

5.  The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.

Authors:  Yusuke Tomita; Min-Jung Lee; Sunmin Lee; Saori Tomita; Saranya Chumsri; Scott Cruickshank; Peter Ordentlich; Jane B Trepel
Journal:  Oncoimmunology       Date:  2016-08-31       Impact factor: 8.110

Review 6.  Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.

Authors:  Clizia Zichi; Marcello Tucci; Gianmarco Leone; Consuelo Buttigliero; Francesca Vignani; Daniele Pignataro; Giorgio V Scagliotti; Massimo Di Maio
Journal:  Biomed Res Int       Date:  2017-06-07       Impact factor: 3.411

7.  Transcriptional Profiling of Advanced Urothelial Cancer Predicts Prognosis and Response to Immunotherapy.

Authors:  Seung-Woo Baek; In-Hwan Jang; Seon-Kyu Kim; Jong-Kil Nam; Sun-Hee Leem; In-Sun Chu
Journal:  Int J Mol Sci       Date:  2020-03-08       Impact factor: 5.923

Review 8.  Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective.

Authors:  Chiara Donini; Ramona Rotolo; Alessia Proment; Massimo Aglietta; Dario Sangiolo; Valeria Leuci
Journal:  Cells       Date:  2021-03-04       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.